Clinical Trial Update: ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ctDNA-guided omission of chemotherapy in combination with ribociclib and endocrine therapy for HR-positive/HER2-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING